Introgen strikes nanotech deal with MD Anderson
17th Nov 2006, 04:34 GMT
Introgen Therapeutics an Austin biotech company working on novel cancer therapies, has obtained an exclusive, worldwide license to a portfolio of patents from The Univ of TX MD Anderson Cancer Center in Houston.
Latest news from Financial News News from StratCenter.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris